Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum : A Novel Insight into Endothelial and Cardiac Cells Phenotype in Systemic Sclerosis Using Patient-Derived.

Cell journal·2026
Same author

Human pluripotent stem cell-derived neuroepithelial cells develop into an organizer for optic tectum formation in the chicken diencephalon.

Frontiers in cell and developmental biology·2026
Same author

Targeting PCSK9, APOB, and CETP at the Transcriptome Level by hsa-miR-30b-3p Reduces LDL-Associated Protein in Huh-7 Cells.

Molecular biology reports·2026
Same author

Safety and feasibility of allogenic keratinocyte sheet application for deep second degree burn; SAFEALLOSHEET: phase I clinical trial.

Regenerative medicine·2026
Same author

The harmonies played by miR-302/367 cluster in pluripotency, reprogramming, and rejuvenation.

Stem cells translational medicine·2026
Same author

Dynamic proteome profiling of differentiating human embryonic stem cells towards cardiomyocytes.

Scientific reports·2025
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

2.7K

Allogeneic cell therapy manufacturing: process development technologies and facility design options.

Saeed Abbasalizadeh1,2, Mohammad Pakzad1, Joaquim M S Cabral2

  • 1a Department of Stem Cells and Developmental Biology, Cell Science Research Center , Royan Institute for Stem Cell Biology and Technology, ACECR , Tehran , Iran.

Expert Opinion on Biological Therapy
|July 13, 2017
PubMed
Summary
This summary is machine-generated.

Allogeneic cell therapies show promise, driving investment in large-scale production. Developing safe, effective cell products requires robust manufacturing processes and facilities compliant with GMP regulations.

Keywords:
Allogeneic cell therapycommercializationfacility designprocess development

More Related Videos

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.8K
A GMP-Compliant Procedure for the Generation of Gene-Modified T cells
06:47

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

1.1K

Related Experiment Videos

Last Updated: Feb 26, 2026

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
09:03

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

2.7K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.8K
A GMP-Compliant Procedure for the Generation of Gene-Modified T cells
06:47

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

1.1K

Area of Science:

  • Regenerative Medicine
  • Cell Therapy Manufacturing
  • Biopharmaceutical Development

Background:

  • Clinical trials show promising outcomes for allogeneic cell therapies, including mesenchymal stromal cells, fibroblasts, keratinocytes, and cardiac stem cells.
  • Increased investment from research institutions, SMEs, and pharmaceutical companies is focused on developing allogeneic cell therapy products.
  • Commercialization necessitates advanced capabilities for generating safe, effective, and characterized allogeneic cell lines and banks.

Purpose of the Study:

  • To review recent advances in allogeneic product development.
  • To discuss options for developing robust manufacturing processes for cell therapies.
  • To highlight facility design considerations for cell therapy production.

Main Methods:

  • Review of current literature and industry trends in allogeneic cell therapy.
  • Analysis of manufacturing process development strategies (upstream and downstream).
  • Consideration of facility design principles for GMP-compliant cell therapy production.

Main Results:

  • Significant progress has been made in allogeneic product development, attracting substantial investment.
  • Key areas for development include technology for cell/cell line generation, master/working bank creation, and process optimization.
  • Facility design must integrate manufacturing processes and adhere to GMP regulations for quality and affordability.

Conclusions:

  • The allogeneic cell therapy field is rapidly advancing but faces challenges in technology, regulation, and understanding mechanisms of action.
  • Robust manufacturing processes and well-designed facilities are critical for successful commercialization.
  • Characterization and testing of allogeneic products remain complex and evolving areas.